Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEL-Y01 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT06247345Phase 1Terminated
- Sponsor
- Alzheimer's Disease Expert Lab
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADEL-Y01 in Alzheimer's disease (AD) (16 cohorts), sponsored by Alzheimer's Disease Expert Lab. Primary endpoint: Safety and Tolerability at 22 weeks. Started Feb 2024; status: terminated.
02
Drugs
ADEL-Y01
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06247345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247345.